Safety, immunization coverage and determinants of a new kind of Hepatitis B vaccine firstly applied in Ningbo, China
- PMID: 26211419
- PMCID: PMC4916460
- DOI: 10.1080/21645515.2015.1066946
Safety, immunization coverage and determinants of a new kind of Hepatitis B vaccine firstly applied in Ningbo, China
Abstract
Evaluate safety and immunization coverage of a new kind of recombinant Hepatitis B vaccine (HepB) in Ningbo city, China. Two groups were carried out in 2 of 11 randomly selected countries in Ningbo in 2009. All of the infants born from July 1 to December 31, 2009 were enrolled as subjects and received 3 doses of HepB at 0, 1, 6 month. Control group (N = 3452) received current HepB derived from Saccharomyces Cerevisiae Yeast (HepB made by recombinant DNA techniques in Saccharomyces Cerevisiae Yeast, HepB-SCY; 5 μg/0.5 ml per dose) and experimental group (N = 5104) received the new kind of HepB derived from Hansenula polymorpha Yeast (HepB made by recombinant DNA techniques in Hansenula polymorpha Yeast, HepB-HPY; 10 μg/0.5 ml per dose). 3-dose and timely birth dose (TBD) coverage were available and compared between 2 groups. Standard structured questionnaires were applied to record information from parents and hospitals for selecting determinants of coverage. The data were analyzed using stepwise multiple logistic regression models. After each dose, HepB-related adverse events (AEs) and recta-temperature were recorded for 7 days. 3-dose coverage in control group (89.98%) was higher than that in experimental group (χ2 = 575.1173, P < 0.0001). TBD coverage in control and experimental group were 98.41% and 98.53%, respectively. No statistically significant difference in TBD coverage was found between 2 groups (χ2 = 0.0623, P = 0.8029). A total of 9 local AEs were reported, 4 for control group and 5 for experimental group. The percentages of subjects reporting AEs were similar across the 2 vaccination groups. No serious or immediate reactions were found in this study. From logistic models, receiving 10 μg vaccine (odds ratio [OR]:0.38; 95% confidence interval [95%CI]: 0.34-0.44) and mother migrating from other cities (OR: 0.45; 95%CI: 0.42-0.47) were the determinants for non-acceptance of 3 doses of HepB; infants born from low grade hospitals and native mothers contributed to administrate the TBD.
Keywords: coverage; determinants; hepatitis b vaccine; infants; safety.
Similar articles
-
[Anti-HBs persistence following primary vaccination with three doses of hepatitis B vaccine among normal and high-responder adults: a 3-year follow-up study].Zhonghua Yu Fang Yi Xue Za Zhi. 2016 Jun;50(6):478-83. doi: 10.3760/cma.j.issn.0253-9624.2016.06.002. Zhonghua Yu Fang Yi Xue Za Zhi. 2016. PMID: 27256725 Chinese.
-
[Anti-HBs persistence following revaccination with three doses of hepatitis B vaccine among low-responsive adults after primary vaccination: a 4-year follow-up study].Zhonghua Yu Fang Yi Xue Za Zhi. 2016 Jun;50(6):491-6. doi: 10.3760/cma.j.issn.0253-9624.2016.06.004. Zhonghua Yu Fang Yi Xue Za Zhi. 2016. PMID: 27256727 Chinese.
-
[Anti-HBs persistence after revaccination with three doses of hepatitis B vaccine among non-responsive adults: a 4-year of follow-up study].Zhonghua Yu Fang Yi Xue Za Zhi. 2016 Jun;50(6):497-502. doi: 10.3760/cma.j.issn.0253-9624.2016.06.005. Zhonghua Yu Fang Yi Xue Za Zhi. 2016. PMID: 27256728 Chinese.
-
A retrospective study of hepatitis B vaccination in preterm birth and low birth weight infants born to hepatitis B surface antigen-positive mothers: Time to close the policy-practice gap.Hum Vaccin Immunother. 2022 Dec 30;18(7):2155390. doi: 10.1080/21645515.2022.2155390. Epub 2022 Dec 14. Hum Vaccin Immunother. 2022. PMID: 36514905 Free PMC article. Review.
-
The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization.Vaccine. 2013 Dec 27;31 Suppl 9:J15-20. doi: 10.1016/j.vaccine.2013.03.045. Vaccine. 2013. PMID: 24331015 Review.
Cited by
-
Hepatitis B Vaccination among 1999⁻2017 Birth Cohorts in Zhejiang Province: The Determinants Associated with Infant Coverage.Int J Environ Res Public Health. 2018 Dec 19;15(12):2915. doi: 10.3390/ijerph15122915. Int J Environ Res Public Health. 2018. PMID: 30572681 Free PMC article.
References
-
- Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014;9938:2053-63; http://dx.doi.org/10.1016/S0140-6736(14)60220-8 - DOI - PubMed
-
- Ganem D, Prince AM. Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med 2004; 350:1118-29; PMID:15014185; http://dx.doi.org/10.1056/NEJMra031087 - DOI - PubMed
-
- Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2:395-403; PMID:12127351; http://dx.doi.org/10.1016/S1473-3099(02)00315-8 - DOI - PubMed
-
- Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Shau WY, Liang DC Chen DC. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9; PMID:9197213; http://dx.doi.org/10.1056/NEJM199706263362602 - DOI - PubMed
-
- Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001; 139:349-52; PMID:11562612; http://dx.doi.org/10.1067/mpd.2001.116277 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical